Detection of human T-Cell lymphotropic virus Type-I provirus DNA by in vitro enzymatic amplification
β Scribed by Nobuyuki Fujii; Masanori Ogasawara; Dr. Satoru Ito; Mitsutoshi Tara
- Book ID
- 102878356
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 939 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
β¦ Synopsis
For the detection of the HTLV-I provirus genomic DNA, we applied the polymerasechain-reaction (PCR) dot-blot assay system developed by Saiki et al. (14). DNA sequences coding the p24 in the gag region were chosen as targets to be amplified. We checked genomic DNAs extracted from peripheral blood lymphocytes (PBL) of five adult T-cell leukemia patients, one HTLV-I-associated myelopathy (HAM) patient, four asymptomatic carriers, and five normal individuals as negative controls. Although carriers sometimes showed low antibody titers in the particle-agglutination Kev words:
adult T-cell leukemia, test and revealed faint banding patterns in Western-blot analysis, the PCR dot-blot assay system can clearly detect the HTLV-I provirus DNA. Furthermore, all data obtained with the specimens tested were confirmed by the PCR oligomer-restriction (OR) procedure.
The PCR dot-blot assay system is simple and rapid for the detection of the target DNA sequence, although it does not provide useful additional information, as does the Southern-blot analysis. Therefore, it can be considered to be a powerful analytical system for the confirmation of HTLV-I infections.
HTLV-I-associated rnveloDathv. enzvmatic polymerization, dot-blot assay, oligonucleotide probe, genomk structure
π SIMILAR VOLUMES
Publication of the International Union Against Cancer Publication de I'Union lnternationale Contre le Cancer
## Abstract Human Tβcell lymphotropic virus type I (HTLVβI) is the etiologic agent of HTLVβIβassociated myelopathy/tropical spastic paraparesis (HAM/TSP). High HTLVβI provirus load and __tax__ mRNA level have been suggested as predictors of disease progression in patients with HAM/TSP, but little i